NMC Healthcare is UAE’s largest private healthcare provider. It has two main branches of business, NMC Healthcare and NMC Trading.
From a one room clinic in Abu Dhabi to a global healthcare enterprise in 40 years – this is the journey called NMC.
Since its inception, NMC has been chalking out distinct growth strategies that reflect the continuing leadership in the market. Having focused on expanding the capacities and building new capabilities, NMC has developed specialised verticals covering multi-specialty care, maternity and fertility, long-term and home care, operations and management and distribution services.
Over the years, NMC has earned the trust of millions, thanks to its personalised care and a sincere commitment to the overall well-being of the community it serves.
With a team of over 2,000 doctors and 18,000 paramedical and support personnel, NMC owns and manages over 135 healthcare facilities that includes hospitals, medical centres, long term care facilities, day surgery centres, fertility centres and home health services providers.
Every year, over 8.5 million patients are treated by NMC doctors across UAE, Saudi Arabia, Kuwait, Oman, UK, Spain, Italy, Denmark, Slovakia, Egypt, Brazil and Colombia.
NMC was the first company from Abu Dhabi to list on the London Stock Exchange and is now part of the FTSE 100 Index, an elite club of top 100 blue-chip companies by market cap.

Update of group strategy.

////////////////////////////////////////////////////////////////////////////////////////////////

16 Feb Jefferies... 600.00 Buy

Full year results

Acquisition of Clinica Eugin
RNS
RNS Number : 6648F
NMC Health Plc
24 February 2015





24 February 2015

NMC HEALTH PLC ANNOUNCES THE ACQUISITION OF LEADING GLOBAL FERTILITY CENTRE

NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated private healthcare provider operating across the United Arab Emirates, is pleased to announce that it has entered into an agreement to acquire 86.4% of issued share capital of Clinica Eugin ('Eugin'), a leading global fertility treatment provider based in Barcelona, Spain, for an Enterprise Value of €143m. Eugin is one of the largest fertility clinics in Europe and the established leader in cross-border fertility treatment with patients from the largest Western European countries, as well as the MENA region. The shares are to be acquired from ProA Capital, Eugin's founders and members of the Eugin management team.

The acquisition of Eugin allows NMC to achieve several key elements of its recently updated Group Strategy and is supported by a strong strategic rationale:

· Eugin is a leading IVF centre of excellence with world-leading technology and expertise as well as strong brand recognition

· Brings leading global expertise and technologies in fertility services to NMC's network in the UAE and strongly complements existing NMC women's health services

· Accelerates the development of NMC into a centre of clinical excellence for women's health and will allow NMC to establish a foothold in the UAE medical tourism market

· Significant potential for revenue synergies from growing Eugin's franchise in the UAE and the broader GCC/MENA region

· Transaction expected to be significantly accretive in Year 1 with positive effect on margins and attractive ROIC

· Eugin's strong and experienced management team have agreed to remain at the Company, limiting potential integration risk

Furthermore, in line with NMC's Group Strategy, the Company is also in discussion with multiple parties regarding potential acquisition opportunities in the UAE and GCC region, which would allow NMC to increase its scale across the region as well as further maximise operational synergies. These discussions remain at a preliminary stage and there is no certainty that any of these discussions will lead to additional announced transactions.





Dr. B.R. Shetty, Chief Executive Officer, commented:

"The acquisition of Eugin represents a unique juncture in the history of NMC, combining the leading UAE hospital franchise with a leading global fertility franchise. This transaction offers NMC the opportunity to become the leading integrated women's health provider from fertility through obstetrics and paediatrics in the UAE, and also establishes a foothold for the Company in the growing medical tourism market. The acquisition is expected to be accretive within the first year, and further progresses NMC's strategy of creating centres of excellence across a number of clinical specialties".



Market Opportunity in the UAE fertility sector

Infertility is a growing medical issue within the UAE and, according to Frost & Sullivan ('F&S'), it is estimated that the total fertility rate (number of children per woman) in the country has declined from 2.7 in the year 2000 to 1.7 in 2010, with approximately one in six couples experiencing fertility problems. Furthermore, there is an acute shortage of world class fertility treatment facilities in the country with F&S estimating a supply/demand shortfall of 8,500 IVF cycles in 2013, which represented over 50% of the total demand for IVF treatment in that year.

The infertility market in the UAE is also expected to be driven by the growing medical tourism sector in Dubai. Dubai Health Authority has announced plans to attract 500,000 medical tourists by 2020, generating over $700m in revenues. As of 2014, infertility procedures have also been identified by Dubai Health Care City's (DHCC) recent survey as the leading treatment sought by medical tourists visiting the Emirate.



Information on Clinica Eugin

Based in Barcelona and founded in 1999, Eugin is amongst the largest European providers of fertility treatments, in terms of the number of cycles performed annually, and has the largest egg bank in Europe providing c.10% of donor IVF treatments in Europe. The Company is also the leader in cross-border fertility treatments in Europe. In 2014, the clinic treated more than 5,000 patients and carried out over 8,000 cycles. The clinic offers a full range of fertility treatments including intra-uterine insemination (IUI), in-vitro fertilisation (IVF), intra-cytoplasmic sperm injection (ICSI), fertility preservation and genetic screening.

Over 95% of Eugin's patients are referred from outside Spain with France (55%), Italy (17%), Switzerland (4%), MENA (3%) and the UK (2%) representing the main countries of origin for the patients. Almost all of Eugin's revenues are derived from privately insured or cash pay patients.

Eugin has been majority-owned by ProA Capital since 2010. Eugin's current senior management, Andres Rebage (General Operational Manager) and Dr. Valerie Vernaeve (General Medical Manager), have been with Eugin for several years and have agreed to continue to manage, and retain an investment, in the business.

For the twelve months ended 31 December 2014, Eugin reported revenues of €34.3m, EBITDA of €14.0m and EBITDA margins of 41.0%. As of 31 December 2014, Eugin had gross assets of €59.0m and approximately 230 employees.



Financing and Financial Impact on NMC

NMC will finance the transaction using existing cash and credit facilities. NMC expects to retain post transaction, a net debt to EBITDA level allowing the Company financial flexibility for future growth initiatives. In this transaction, NMC has not utilised any of the funds made available through the US$ 825m facility announced on 16 February 2015.

Excluding synergies, the transaction is expected to be significantly accretive to NMC's EPS.



Additional Information on the Transaction

The Transaction is subject to customary terms and conditions. The transaction was signed and closed simultaneously on 23 February, 2015.

HSBC is acting as Financial Advisor and Evercore Partners is acting as Strategic Advisor to NMC. In addition, NMC is being advised by Allen & Overy and PwC.

NMC Health plc will host a webcast and conference call presentation for investors and analysts today at 14.00 UK time. There will be a short presentation by management covering the FY 2014 results and this transaction followed by a Q&A session.



The call will be hosted by:

Mr Prasanth Manghat, Deputy CEO

Mr Suresh Krishnamoorthy, Chief Financial Officer

Mr Roy Cherry, Head of Strategy & IR







Date and time:

Date Tuesday 24 February 2014

Time 14.00 GMT (09.00 EDT, 18.00 UAE)









- ends -

24 Feb Investec N/A Buy
24 Feb Numis 620.00 Buy

25 Feb Jefferies... 800.00 Buy

Director/PDMR Shareholding
RNS
RNS Number : 9864F
NMC Health Plc
26 February 2015













NMC Health plc



NOTIFICATION MADE IN ACCORDANCE WITH RULE 3.1.4 (1) (a) OF THE

DISCLOSURE AND TRANSPARENCY RULES





London, 26 February 2015: NMC Health plc (LSE:NMC) ('NMC'), the leading integrated private sector healthcare operator in the United Arab Emirates, announces that it was notified on 26 February 2015 that the following director purchased ordinary shares of 10p each in the Company ("Shares"). The Shares were purchased at a price of 558 pence per Share.



Director
Position
No. of Shares purchased

Heather Lawrence
Independent Non-Executive Director
1,790




Following this purchase, Mrs Lawrence has an interest in a total of 6,347 Shares, representing approximately 0.01% of the issued share capital of the Company.

Naked Trader today - I've bought into NMC Health (LON:NMC)



I really like the middle east medcare sector at the moment. There is a massive catalyst for growth in that Dubai is rolling out mandatory healthcare insurance over the next couple of years which should see shares in NMC continue to rise - and also that of Al Noor which I bought last time and have a load of from lower.

The shares don't on the face of it look cheap - but remember the market looks forwards and it is eyeing up the benefits due from mandatory heathcare.

I think both NMC and ANH will boom (boom shake the room). (Tick, tick, tick.. boom...) (that's enough aged dance music references)

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 658.00. Over this period, the share price is up 19.54%.

18 Mar Numis 800.00 Buy

Two acquisitions

29 Apr Investec N/A Buy
29 Apr Numis 880.00 Buy

30 Apr Investec 900.00 Buy

5 May Jefferies... 1,000.00 Buy

NMC Health PLC (NMC:LSE) set a new 52-week high during today's trading session when it reached 869.50. Over this period, the share price is up 86.59%.

Acquisition of Pro Vita

Statement re Possible Offer
RNS
RNS Number : 8442B
Al Noor Hospitals Group PLC
09 October 2015



NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION



THIS ANNOUNCEMENT IS NOT AN ANNOUNCEMENT OF A FIRM INTENTION TO MAKE AN OFFER UNDER RULE 2.7 OF THE CITY CODE ON TAKEOVERS AND MERGERS (THE "CODE") AND THERE CAN BE NO CERTAINTY THAT AN OFFER WILL BE MADE, NOR AS TO THE TERMS ON WHICH ANY OFFER WILL BE MADE



FOR IMMEDIATE RELEASE

October 9th, 2015



The Board of Al Noor Hospitals Group Plc (the "Company") notes the recent media speculation in relation to the Company and confirms that it has received an approach from NMC Health Plc ("NMC") regarding a possible offer.



In accordance with Rule 2.6(a) of the Code, NMC is required, by not later than 5.00 p.m. on November 6th, 2015, to either announce a firm intention to make an offer for the Company in accordance with Rule 2.7 of the Code or announce that it does not intend to make an offer, in which case the announcement will be treated as a statement to which Rule 2.8 of the Code applies. This deadline can be extended with the consent of the Panel in accordance with Rule 2.6(c) of the Code.

NMC Health remains committed to a combination
StockMarketWire.com
NMC Health notes the announcement today by Al Noor Hospital Group and Mediclinic International Ltd.

"This confirms our belief in the competitiveness of our initial possible offer and that the combination of NMC and Al Noor has the strongest strategic and financial rationale for all stakeholders," it said in a statement.

"We reiterate our commitment to this opportunity despite the lack of meaningful engagement from the Board of Al Noor.

"We plan to issue a further announcement in due course. We would urge shareholders to take no action at this time."



At 9:22am:
(LON:ANH) Al Noor Hospitals Group PLC share price was +134p at 1128.5p
(LON:NMC) NMC Health PLC share price was +20p at 828.5p


Story provided by StockMarketWire.com

Company News

NMC Health abandons bid for Al Noor Hospitals

Mon, 16 November 2015




(ShareCast News) - NMC Health has abandoned its bid for Al Noor Hospitals, meaning South Africa's Mediclinic International looks set to clinch a deal with the Abu Dhabi-based healthcare operator.
Al Noor confirmed in early October that it had received an approach from NMC regarding a possible offer.

NMC said on Monday: "After a thorough assessment of the opportunity, NMC has concluded that the potential transaction would not deliver sufficient returns or shareholder value in line with its stated policy, and accordingly NMC now confirms that it does not intend to make an offer for Al Noor."

Last month, the boards of Al Noor and Mediclinic reached an agreement on the terms of a possible merger.

Under the proposed deal announced, Al Noor will acquire Mediclinic, with shareholders receiving 0.625 new shares for each Mediclinic share held.

The proposed deal will result in Mediclinic shareholders owning 84% to 93% of the enlarged group.

The groups said the merger will create a "leading international private healthcare group with deep operational expertise and a well-balanced geographic profile in Southern Africa, Switzerland and the United Arab Emirates".

At 1450 GMT, NMC Health shares were up 1.9% to 773.50p, while Al Noor was flat at 1,158p

Company News

NMC Health focuses on organic expansion after ditching Al Noor bid

Thu, 19 November 2015


NMC Health focuses on organic expansion after ditching Al Noor bid
(ShareCast News) - Emirates-based healthcare provider NMC Health reiterated its commitment to expanding capacity in the UAE and elsewhere, having announced earlier in the week that it had abandoned its bid for Al Noor Hospitals.
NMC said on Monday that after a thorough assessment of the opportunity, it had concluded that the potential transaction with Al Noor "would not deliver sufficient returns or shareholder value in line with its stated policy".

On Thursday, it looked as though the company was putting all that behind it.

The group said it has reviewed and assessed multiple proposed inorganic, organic and partnership opportunities over the past year and continues to be highly selective and disciplined in its investment process.

Deputy chief executive Prasanth Manghat said: "Over the past year we continued to execute our updated strategy in a highly dedicated and methodical manner with full focus on meeting our strategic objectives and delivering sustainable long-term growth, strategic and competitive advantages and shareholder returns.

"We look to the future and continue to see very favourable healthcare market dynamics and substantial growth opportunities for NMC Health in the UAE and the wider region."

NMC said it has completed four strategic and value-accretive acquisitions in the year to date, including fertility treatment company Clinica Eugin, ventilated care provider ProVita, homecare services provider Americare and UAE-based primary care provider Dr. Sunny Network.

The company expects to have 885 licensed beds available by the end of this year and a network of medical centres and day surgeries.

At 1430 GMT, NMC shares were down 0.4% at 764p.

Acquisition
RNS
RNS Number : 7427G
NMC Health Plc
24 November 2015



24 November 2015 - NMC Health plc expands its Maternity & Fertility vertical through the acquisition of a majority stake in Fakih IVF

NMC Health plc (LSE:NMC) ('NMC' or the 'Company'), the leading integrated healthcare provider operating across the United Arab Emirates, is pleased to announce that it has entered into an agreement to acquire a 51% shareholding in Fakih IVF Group ('Fakih IVF') for AED696m (US$189 m). NMC has also agreed a mechanism by which it could increase its stake in Fakih IVF over time, based on certain conditions being met. Based on unaudited management accounts, Fakih IVF generated an EBITDA of US$25m for the nine months ended 30 September 2015, an increase of 20% year-on-year (YoY).

Fakih IVF, which comprises of Fakih IVF LLC and Fakih IVF Fertility Center LLC, is the Middle East market leader for in-vitro fertilisation (IVF) services, performing over 4,000 IVF cycles per annum and offering the only full service genetics laboratory in the region. Fakih IVF currently operates centres in both Abu Dhabi and Dubai and is looking to expand its footprint within the UAE as well as in the Gulf Cooperation Council (GCC) region. Fakih IVF is expected to open three additional UAE centres during 2016 in Al Ain city, Western region of Abu Dhabi Emirate and Sharjah. Fakih IVF has also achieved considerable progress in its regional expansion plan with IVF centres expected in both Qatar and Oman before year end 2016.

The transaction is aligned with NMC's Group strategy of establishing the company as a top in-class integrated provider of specialist care across its existing multi-brand and multi-segment healthcare verticals. This acquisition confirms the NMC Maternity & Fertility vertical's global market position, as one of the leading international providers of fertility treatment services based on;

§ Scale of its global business and cycle capacity

§ Focused strategic initiative towards raising capabilities and access to care in high growth and under-supplied markets

§ Segment leading treatment capabilities and success rates

§ Diversity and complexity of service offering across the fertility treatment spectrum

§ Established presence and referral centres across regulatory geographies to facilitate one-stop approach for patients

NMC Maternity & Fertility vertical now includes:

§ Brightpoint Royal Women's Hospital - Most advanced women's and maternity care hospital in the Middle East

§ Clinica Eugin - Top global fertility care provider based in Europe

§ Fakih IVF (51%) - UAE based Middle Eastern leader with the only full service genetics laboratory in the region

The combination with Fakih IVF is expected to be highly synergistic with significant potential for cross-referral of patients and transfer of best practices and technologies within NMC's Maternity & Fertility vertical. Patients will have access to an integrated continuum of care with complementing capabilities and coordinated seamless service offering including local IVF treatments of the highest international standards at Fakih IVF, international referral to Clinica Eugin and its wider fertility service offering as permitted by its operational and regulatory environment and NMC's hospitals, led by Brightpoint, for antenatal, delivery and postnatal services.

Furthermore, this transaction will increase the company's penetration into the Thiqa insurance segment, which is exclusively comprised of UAE nationals in Abu Dhabi, where fertility treatment is covered.

In addition, fertility treatments are one of the leading drivers of medical tourism in the UAE and the acquisition of Fakih IVF will position NMC as the destination of choice for fertility treatments with a complete service offering delivered by Fakih IVF and Clinica Eugin.

Over 50% of patients treated by Fakih IVF in Dubai are expatriates with over 25% being medical tourists. Approximately 80% of patients treated by Fakih IVF in Abu Dhabi are Emirati nationals covered by Thiqa insurance.

Dr. Michael Fakih, the founder and 100% beneficial owner of Fakih IVF, will remain as a 49% shareholder and Managing Partner in the business, thereby ensuring a smooth transition and limiting any potential integration risk. Dr. Fakih is also a renowned research professional with over a hundred international publications. He has been instrumental in his professional career for over 20,000 births from infertile couples using only IVF.

Dr. B.R. Shetty, Chief Executive Officer at NMC Health, commented:

"Our acquisition of a major shareholding in Fakih IVF is the logical next step towards achieving NMC's goal of becoming a global leader in maternity and fertility services. We are particularly excited about growing our in vitro fertilisation service offering within the UAE and look forward to further expand its geographic reach."

Information on Fakih IVF

Fakih IVF Group was founded in Dubai in 2011 by Dr. Michael Fakih, who has been established as a leading IVF physician in the USA and the UAE for over 20 years. The business expanded into Abu Dhabi in 2013 and currently performs over 4,000 IVF cycles per annum in the UAE. Fakih IVF offers a wide range of IVF-related services including intra-cytoplasmic sperm injection (ICSI), intrauterine insemination (IUI), genetic testing, minimal stimulation IVF and male infertility treatments.

The business has one of the highest success rates for IVF services in the country and is the only IVF centre in the Middle East with an in-house Genetics Laboratory performing genetics screening for couples, embryos and also for the advanced personalised medicine. Fakih IVF was also the first to introduce the EmbryoScope in the UAE, a ground-breaking technology in the field of reproductive medicine and was the first centre in the UAE to perform a MicroTESE, a procedure that allows for sperm to be found even if sperm retrievals done earlier did not produce viable sperm for IVF.

Fakih IVF generated a net profit of US$16.6m and had gross assets of US$17.6m and net assets of US$13.7m in the financial year ended 31 March 2014.

Fakih IVF is expected to have a net cash position on its balance sheet at the time of closing.

Website: fakihivf.com

Financing and Financial Impact on NMC

The transaction will be financed using existing cash and credit facilities. NMC expects to retain, post transaction, a net debt to EBITDA level allowing the company financial flexibility for future growth initiatives.

Excluding synergies, the transaction is expected to be significantly accretive to NMC's EPS in 2016 with an attractive ROIC in excess of NMC's cost of capital.

Additional Information on the Transaction

The transaction is subject to customary terms and conditions. NMC expects the transaction to complete by the end of Q1 2016.

Evercore and FGB are acting as Financial Advisors to NMC. In addition, NMC is being advised by Allen & Overy, Clyde & Co. and PwC.